Last reviewed · How we verify
GP Combined With Camrelizumab
GP (gemcitabine/cisplatin chemotherapy) combined with camrelizumab (a PD-L1 inhibitor) works by killing cancer cells directly while simultaneously unleashing immune responses against tumors.
GP (gemcitabine/cisplatin chemotherapy) combined with camrelizumab (a PD-L1 inhibitor) works by killing cancer cells directly while simultaneously unleashing immune responses against tumors. Used for Likely advanced or metastatic solid tumors (specific indication under phase 3 evaluation not definitively confirmed in public sources).
At a glance
| Generic name | GP Combined With Camrelizumab |
|---|---|
| Sponsor | XIANG YANQUN |
| Drug class | Chemotherapy + PD-L1 inhibitor combination |
| Target | PD-L1 (camrelizumab component); DNA (gemcitabine/cisplatin component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine and cisplatin are cytotoxic chemotherapy agents that damage DNA and induce apoptosis in rapidly dividing cancer cells. Camrelizumab is a humanized monoclonal antibody that blocks PD-L1, removing the inhibitory signal that tumors use to evade immune attack, thereby restoring T-cell-mediated anti-tumor immunity. The combination leverages both direct cytotoxicity and immunotherapy synergy.
Approved indications
- Likely advanced or metastatic solid tumors (specific indication under phase 3 evaluation not definitively confirmed in public sources)
Common side effects
- Myelosuppression (anemia, thrombocytopenia, neutropenia)
- Nausea and vomiting
- Fatigue
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Nephrotoxicity (cisplatin-related)
Key clinical trials
- Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma (PHASE3)
- Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial (PHASE3)
- Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy (PHASE3)
- A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP Combined With Camrelizumab CI brief — competitive landscape report
- GP Combined With Camrelizumab updates RSS · CI watch RSS
- XIANG YANQUN portfolio CI